The Foundation for Vaccine Research - Working to Secure Our Children's Future
Photo: Clive Gray, Cape Town

If a Job’s worth doing,
it’s worth doing well

Our website is being redesigned to improve performance and readability on all devices. It will relaunch shortly.

Latest News

23 July 2015

Call for establishing a global vaccine development fund published in the New England Journal of Medicine.

Plotkin SA, Mahmoud AAF, Farrar J. Establishing a global vaccine development fund. N Engl J Med. 2015 Jul 23;373(4):297-300

See updated list of diseases and infections uncontrolled by vaccination.

Supplement to the N Engl J Med article

Audio interview with Dr. Stanley Plotkin, Emeritus Professor, University of Pennsylvania, and a Director, Foundation for Vaccine Research, on a strategy for stimulating and supporting global vaccine research. (9:21)



Vaccine-Preventable Diseases and Infections and Targets Currently Uncontrolled by Vaccination. Updated August 21, 2015.*

Diseases and infections with commonly used vaccines

  • Diphtheria
  • Haemophilus influenzae type b
  • Hepatitis type A
  • Hepatitis type B
  • Human papillomavirus (HPV)
  • Influenza types A and B (seasonal)
  • Japanese encephalitis
  • Measles
  • Meningococcus
  • Mumps
  • Pertussis (whooping cough)
  • Polio
  • Pneumoccocus
  • Rabies
  • Rotavirus
  • Rubella
  • Smallpox
  • Tetanus
  • Tickborne encephalitis
  • Typhoid
  • Varicella (chickenpox)
  • Yellow fever

Diseases and infections with limited-use vaccines

  • Adenovirus types 4 and 7
  • Anthrax

Diseases and infections with no vaccines or only partially effective vaccines

  • Campylobacter
  • Cancer
  • Candida
  • Chikungunya
  • Chlamydia Moraxella
  • Clostridium difficile
  • Cryptosporidium
  • Cytomegalovirus
  • Dengue
  • Ebola and viral hemorrhagic fevers
  • Enterovirus including EV71, EV68, CA16
  • Epstein-Barr virus
  • Escherichia coli
  • Haemophilus influenzae, nontypable
  • Helicobacter
  • Helminths (numerous)
  • Hendra virus
  • Hepatitis type C
  • Hepatitis type E
  • Herpesvirus type 6
  • Herpes simplex
  • Influenza, universal
  • Influenza, avian types H5 and H7
  • Leishmaniasis
  • Lyme disease
  • Malaria
  • MERS
  • Metapneumovirus
  • Moraxella (for otitis)
  • Neisseria gonorrhoeae
  • Nipah virus
  • Norovirus
  • Nosocomial bacteria
  • Parainfluenza
  • Plague
  • Rhinovirus
  • RSV
  • Salmonella paratyphi
  • SARS
  • Schistosomiasis
  • Shigella
  • Staphylococcus
  • Strep Group A
  • Strep Group B
  • Toxoplasmosis
  • Trypanosomiasis
  • Tuberculosis
  • West Nile virus

* Updated information is from the Foundation for Vaccine Research. Nipah and Hendra viruses were unintentionally omitted in the list published in NEJM. MERS denotes Middle East Respiratory Syndrome, RSV Respiratory Syncytial Virus, and SARS Severe Acute Respiratory Syndrome. Vaccines for some of the targets indicated above are in advanced development, but most are not.

News Update

21 August 2015

Support builds for reform of vaccine development through proposed fund.

See editorial in The New York Times; see articles in The New York Times, The Wall Street Journal, The Guardian, Reuters, Business Insider, CIDRAP News, and Fierce Vaccines.


Global Dispatches Podcast

Interview with Dr. Jeremy Farrar, Professor of Tropical Medicine and Director of the Wellcome Trust, in which he discusses the implications of the recent Ebola vaccine trial and how the creation of a global vaccine development fund will spur the development and deployment of vaccines to counter fast emerging epidemics. (12:00)


News Update

21-22 September 2015

Proposed fund makes its debut at World Bank-WHO meeting in Washington

The FVR’s Stanley Plotkin makes the case for the proposed global vaccine development fund in a special session of the World Bank Group-WHO stakeholders meeting on pandemic financing at the World Bank in Washington.

World Bank Group Headquarters, Washington, DC

News Update

29-30 October 2015

Support for proposed fund grows in Oslo consultation

The FVR’s founder and executive director Peter Hale gives a talk on the proposed vaccine development fund in Oslo at a high-level consultation organized by the WHO and the Norwegian Institute of Public Health on financing for R&D preparedness. The outcome of the consultation will inform the development of a blueprint for accelerating R&D in future epidemics or public health emergencies.

See agenda
See slide presentation

Oslo City Hall and waterfront

News Update

1 November 2015

Foundation hosts second planning meeting of the core group in Dublin

The FVR’s Board Chair Simon Wain-Hobson, Institut Pasteur, and FVR Director Adel Mahmoud, Princeton University, host a planning meeting of the core group driving the proposed vaccine development fund at the Westin Dublin Hotel. Held on the eve of the Princeton-Fung Global Forum 2015 on lessons learned from the Ebola crisis, this highly-productive meeting marked another milestone in the fund’s development with agreement on the need to set up an interim secretariat.

The Dublin meeting follows an inaugural meeting of the core group in a retreat-like setting hosted by Dr. Mahmoud at his home in Princeton on September 12-13. The group has since expanded from five to seven members.

See members of core group.

Global Vaccine Development Fund Working Group

  • Jeremy Farrar MD PhD
  • Tore Godal MD
  • Peter Hale
  • Adel AF Mahmoud MD PhD
  • Peter Piot MD PhD
  • Stanley A Plotkin MD
  • Simon Wain-Hobson DPhil

Contact: Peter Hale
c/o The Foundation for Vaccine Research
Office +1 202 587 2754
Mobile +1 202 297 7458

The Westin Dublin Hotel

First Announcement

15 November 2015

We're moving!

The Foundation will be moving over the Thanksgiving weekend from 1425 K Street NW into sparkling new offices in the Paramount Building at 1775 Eye Street NW in Washington, DC. Please note our new address. Our phone and fax numbers stay the same.

Entrance to the Paramount Building at 1775 Eye Street, Washington, DC

Breaking News

23 November 2015

World-renowned Institut Pasteur is first to endorse the proposed fund

“The Institut Pasteur has been at the forefront of the fight against many epidemics over the past century, most recently against Ebola. Research in vaccinology is at the heart of our legacy and we are significantly reinforcing our efforts in this area. The Institut Pasteur is pleased to support your most valuable efforts to set up a global vaccine development fund. The initiative you have launched is a most important progress for the control of infectious diseases; clearly, this is what should be implemented to meet with the next epidemics, worldwide.”

Professor Christian Bréchot
President, Institut Pasteur

The Institut Pasteur, Paris